Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2024-03-19 00:00:00 ET · period of report 2024-03-15 · accession 0001819790-24-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-19 | 2024-03-15 | TARS | Neervannan Seshadri | COO | M - OptEx | — | +13.2K | 69.6K | +23% | — |
| D | 2024-03-19 | 2024-03-18 | TARS | Neervannan Seshadri | COO | S - Sale+OE | $30.60 | -4,879 | 64.8K | -7% | -$149.3K |
| DM | 2024-03-19 | 2024-03-15 | TARS | Neervannan Seshadri | COO | M - OptEx | $0.00 | -13.2K | 10.2K | -57% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-15 | M | A | 13,245 | — | 69,646 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). (F2) Includes 1,705 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023. |
| 2 | Common | Common Stock | 2024-03-18 | S | D | 4,879 | $30.60 | 64,767 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2024-03-15 | M | D | 8,148 | $0.00 | 24,444 | D | — · — to — | 8,148 Common Stock | (F4) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F6) RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. |
| 4 | Derivative | Restricted Stock Units | 2024-03-15 | M | D | 5,097 | $0.00 | 10,194 | D | — · — to — | 5,097 Common Stock | (F4) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F5) RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. |